Establishing Empirically Informed Definitions for Key Terminology in Pharmaceutical Quality Management

Purpose Clear and consistently applied terminology is essential for effective pharmaceutical quality management. However, key concepts such as quality, quality culture, compliance, beyond compliance, continuous improvement, and operational excellence are often interpreted inconsistently. This conceptual ambiguity hinders regulatory communication, organizational benchmarking, maturity assessments, and the development of robust measurement systems, particularly in support of programs such as the FDA Quality Management Maturity Program. To address this gap, this study proposes empirically informed definitions for six central pharmaceutical quality management concepts. Methods The definitions were derived through a multivocal literature review of 51 academic and grey literature sources and 86 expert interviews from the pharmaceutical and MedTech sectors, with MedTech serving as an external comparator. Results The analysis identified three structural tensions that may help to interpret how terminology is understood: the regulatory nature of the industry, the coexistence of technical and managerial institutional logics, and cross-functional differences between quality and operations functions. These tensions offer a possible explanation for why concepts closely linked to regulatory requirements, such as quality and compliance, were interpreted more consistently than broader concepts such as quality culture and beyond compliance. Conclusion The proposed definitions aim to clarify conceptual boundaries and to align theoretical and practical perspectives, offering a possible shared language for regulatory programs, organizational maturity assessments, and cross-company benchmarking. Evidence-based definitions may strengthen the foundation for pharmaceutical quality management and support the future development of meaningful quantitative performance metrics. Teaser Key pharmaceutical quality concepts are often interpreted inconsistently. This study grounds six of them in literature and expert interviews to propose a shared vocabulary and support harmonization across the indus​try. Summary Pharmaceutical quality management relies on concepts such as quality, quality culture, compliance, beyond compliance, continuous improvement, and operational excellence, yet these terms are often applied inconsistently. This limits clarity in regulatory communication, benchmarking, maturity assessments and measurement systems within programs such as the FDA Quality Management Maturity Program. Drawing on a multivocal literature review of 51 sources and 86 expert interviews, this study proposes definitions that may support clearer regulatory dialogue and more meaningful performance metrics. It also discusses key tensions that may help to interpret why certain terms were understood more consistently than others.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Innovation
Published
2026-11-21
DOI
https://doi.org/10.1007/s12247-026-11172-y
Primary Topic
Management Systems and Quality Improvement
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Establishing Empirically Informed Definitions for Key Terminology in Pharmaceutical Quality Management

Thomas K. Friedli, Jessica Rebecca Helbling
Journal of Pharmaceutical Innovation
Management Systems and Quality Improvement
article

Establishing Empirically Informed Definitions for Key Terminology in Pharmaceutical Quality Management

Thomas K. Friedli, Jessica Rebecca Helbling
article en

Abstract

Purpose Clear and consistently applied terminology is essential for effective pharmaceutical quality management. However, key concepts such as quality, quality culture, compliance, beyond compliance, continuous improvement, and operational excellence are often interpreted inconsistently. This conceptual ambiguity hinders regulatory communication, organizational benchmarking, maturity assessments, and the development of robust measurement systems, particularly in support of programs such as the FDA Quality Management Maturity Program. To address this gap, this study proposes empirically informed definitions for six central pharmaceutical quality management concepts. Methods The definitions were derived through a multivocal literature review of 51 academic and grey literature sources and 86 expert interviews from the pharmaceutical and MedTech sectors, with MedTech serving as an external comparator. Results The analysis identified three structural tensions that may help to interpret how terminology is understood: the regulatory nature of the industry, the coexistence of technical and managerial institutional logics, and cross-functional differences between quality and operations functions. These tensions offer a possible explanation for why concepts closely linked to regulatory requirements, such as quality and compliance, were interpreted more consistently than broader concepts such as quality culture and beyond compliance. Conclusion The proposed definitions aim to clarify conceptual boundaries and to align theoretical and practical perspectives, offering a possible shared language for regulatory programs, organizational maturity assessments, and cross-company benchmarking. Evidence-based definitions may strengthen the foundation for pharmaceutical quality management and support the future development of meaningful quantitative performance metrics. Teaser Key pharmaceutical quality concepts are often interpreted inconsistently. This study grounds six of them in literature and expert interviews to propose a shared vocabulary and support harmonization across the indus​try. Summary Pharmaceutical quality management relies on concepts such as quality, quality culture, compliance, beyond compliance, continuous improvement, and operational excellence, yet these terms are often applied inconsistently. This limits clarity in regulatory communication, benchmarking, maturity assessments and measurement systems within programs such as the FDA Quality Management Maturity Program. Drawing on a multivocal literature review of 51 sources and 86 expert interviews, this study proposes definitions that may support clearer regulatory dialogue and more meaningful performance metrics. It also discusses key tensions that may help to interpret why certain terms were understood more consistently than others.

Journal of Pharmaceutical InnovationVol. 22(1)
University of St.Gallen (CH)
Management Systems and Quality Improvement
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon